Federal cannabis rescheduling is moving again, if only by a few steps. DEA Chief Administrative Law Judge Derek Julius has rejected a bid by rescheduling opponents to reopen hearings for new testimony, breaking a procedural logjam that had frozen the proceeding for weeks. The ruling doesn't settle the underlying question of whether cannabis belongs on Schedule III, but it clears a specific obstacle that had threatened to drag the case out even further.
What the ruling actually resolved
Opponents of rescheduling wanted Julius to reopen the record so they could introduce testimony tied to a federal watchdog report that flagged gaps in how the government handles drug-scheduling procedures. Julius wasn't persuaded. He called some of the requested testimony "immaterial for the narrow purpose of this hearing" and noted that other issues could have been raised earlier in the process. Fair enough - procedurally, that's a reasonable line to draw. Instead of reopening hearings, he agreed to admit the GAO report itself into the administrative record, which is a smaller concession than opponents wanted but not nothing.
Both sides now get a chance to argue, in writing, how much weight that report should carry. Briefs are due October 29, with replies due November 5. Once that window closes, Julius reviews everything and issues a recommendation - nonbinding - to DEA Administrator Terry Cole, who holds the actual decision-making authority on whether broader rescheduling moves forward.
Why operators keep watching the calendar
Medical marijuana at the state level already shifted from Schedule I to Schedule III earlier this year, but that narrower move didn't resolve the bigger question hanging over the industry. With the briefing period stretching past Election Day, nobody realistically expects a final call before the midterms. For an industry that has learned to treat federal timelines with a healthy dose of skepticism, that's not a surprise. It is, however, another few months of operating in limbo.
That limbo has real financial weight. Schedule III status wouldn't legalize cannabis outright, but it would relieve licensed operators of Section 280E, the IRS provision that currently blocks cannabis businesses from taking standard business deductions. For dispensary owners running thin margins against wholesale pricing pressure, excise tax obligations, and rising compliance costs, 280E relief isn't a technicality - it's the difference between a sustainable tax bill and one that eats into working capital every quarter.
Registration questions already surfacing
Several medical cannabis companies have already applied for DEA registration under the Schedule III framework, hoping to position themselves to operate within a federal regulatory system rather than purely at the state level. None have publicly confirmed approval yet. One wrinkle worth flagging for operators: federal restrictions tied to employees with certain felony convictions could complicate registration for companies that have built hiring practices around social equity goals or simply a broader labor pool. That's a compliance detail that deserves attention from HR and legal teams now, not after an application stalls.
The consumer-facing impact remains genuinely uncertain. Schedule III could open research pathways that have been closed for decades, which in turn could improve the evidence base behind medical cannabis products. Separately, Georgia regulators have approved rules permitting medical marijuana deliveries through USPS and other carriers - a notable move given that USPS already allows approved dispensers to mail certain prescription drugs. Whether that becomes a model other states follow, or stays a one-off, is worth watching.
What comes next
The near-term marker is November 5, when reply briefs are due. After that, the timeline gets murky again. Julius's recommendation isn't binding, and Administrator Cole could take his own path regardless of what the record shows. For dispensary operators, multi-state operators, and the compliance teams tracking all of this, the practical advice hasn't changed: plan around current tax and regulatory obligations, not around a rescheduling outcome that remains, for now, still unresolved.
